Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARTIN R BERK

Allopathic & Osteopathic Physicians Internal Medicine Advanced Heart Failure and Transplant Cardiology

NPI
1033118278
CMS profile
92410
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$73,456.60

90 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARTIN R BERK

NPI 1033118278 · CMS profile ID 92410

Allopathic & Osteopathic Physicians / Internal Medicine / Advanced Heart Failure and Transplant Cardiology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033118278?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARTIN R BERK, NPI 1033118278, CMS profile ID 92410. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033118278?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARTIN R BERK, NPI 1033118278, CMS profile ID 92410. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033118278?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARTIN R BERK, NPI 1033118278, CMS profile ID 92410, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–90 of 90 matching records. This page contains 40 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1033118278?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

90 matching records · $73,456.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 90 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–90 of 90.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $110.2407/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321283 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $19.3507/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625124101 CMS
Janssen Pharmaceuticals, Inc $1,200.0007/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321273 CMS
Janssen Pharmaceuticals, Inc $1,200.0007/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321277 CMS
Janssen Pharmaceuticals, Inc $45.0006/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321263 CMS
Janssen Pharmaceuticals, Inc $35.0006/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321265 CMS
Janssen Pharmaceuticals, Inc $50.0006/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321269 CMS
Janssen Pharmaceuticals, Inc $624.7006/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321255 CMS
Janssen Pharmaceuticals, Inc $125.0006/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321259 CMS
Novartis Pharmaceuticals Corporation $3,300.0006/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659047431 CMS
Novartis Pharmaceuticals Corporation $124.1806/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659047435 CMS
Novartis Pharmaceuticals Corporation $10.2906/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659047457 CMS
Novartis Pharmaceuticals Corporation $5.0006/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659047459 CMS
Janssen Pharmaceuticals, Inc $2,000.0006/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321247 CMS
Boston Scientific Corporation $117.4706/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663324903 CMS
Siemens Medical Solutions USA, Inc. $11.7605/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631927097 CMS
Novartis Pharmaceuticals Corporation $78.4005/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658808259 CMS
Novartis Pharmaceuticals Corporation $3,640.0005/03/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658808265 CMS
Novartis Pharmaceuticals Corporation $2.7105/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658808274 CMS
Novartis Pharmaceuticals Corporation $15.0005/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658808281 CMS
Novartis Pharmaceuticals Corporation $330.0005/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658808293 CMS
SANOFI-AVENTIS U.S. LLC $12.1105/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694032327 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $17.8904/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 625124103 CMS
Janssen Pharmaceuticals, Inc $1,200.0004/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321244 CMS
Janssen Pharmaceuticals, Inc $1,200.0004/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321233 CMS
Boston Scientific Corporation $19.4203/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663324877 CMS
Janssen Pharmaceuticals, Inc $1,200.0003/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321229 CMS
Janssen Pharmaceuticals, Inc $1,200.0003/22/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321225 CMS
Boston Scientific Corporation $80.2703/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663324897 CMS
Janssen Pharmaceuticals, Inc $1,200.0003/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321221 CMS
Janssen Pharmaceuticals, Inc $1,200.0002/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321217 CMS
Siemens Medical Solutions USA, Inc. $20.4102/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631927103 CMS
Novartis Pharmaceuticals Corporation $93.6702/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659047427 CMS
Janssen Pharmaceuticals, Inc $1,200.0001/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321207 CMS
Janssen Pharmaceuticals, Inc $1,200.0001/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321211 CMS
Boston Scientific Corporation $142.6601/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663324913 CMS
Janssen Pharmaceuticals, Inc $1,200.0001/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321203 CMS
Janssen Pharmaceuticals, Inc $1,200.0001/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321201 CMS
Janssen Pharmaceuticals, Inc $1,200.0001/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658321196 CMS
Boston Scientific Corporation $120.9401/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663324909 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73,456.60 90
PY2020 $20,308.17 34
PY2021 $21,360.77 32
PY2022 $76,526.93 66
PY2023 $49,394.02 54
PY2024 $94,650.89 71
PY2025 $43,477.63 41

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $192,658.11 80
PY2024 Principal investigator $247,965.62 53
PY2023 Principal investigator $197,818.99 46
PY2022 Recipient $384.00 1
PY2022 Principal investigator $221,447.38 162
PY2021 Recipient $1,641.16 1
PY2021 Principal investigator $256,648.56 307
PY2020 Recipient $1,233.37 1
PY2020 Principal investigator $174,323.77 129
PY2019 Principal investigator $194,786.19 61

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

80 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $32.39 12/31/2025 Non-covered Recipient Entity
TEXAS HEALTH PHYSICIANS GROUP
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310813
Principal investigator 1 Janssen Research & Development, LLC $6,322.00 12/12/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274986
Principal investigator 1 Janssen Research & Development, LLC $3,173.00 11/27/2025 Non-covered Recipient Entity
TEXAS HEALTH RESEARCH & EDUCATION I
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175404192
Principal investigator 1 Janssen Research & Development, LLC $3,611.00 11/19/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275168
Principal investigator 1 Janssen Research & Development, LLC $8,122.00 11/07/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275125
Principal investigator 1 Boehringer Ingelheim International GmbH $675.00 10/22/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635303
Principal investigator 1 Boehringer Ingelheim International GmbH $11,700.00 10/22/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635305
Principal investigator 1 Boehringer Ingelheim International GmbH $5,757.00 10/22/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635307
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635299
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635301
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 09/24/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635291
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 09/24/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635293
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 09/24/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635295
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 09/24/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635297
Principal investigator 1 Janssen Research & Development, LLC $6,897.00 09/19/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274996
Principal investigator 1 Janssen Research & Development, LLC $1,212.00 09/05/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275120
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635283
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635285
Principal investigator 1 Janssen Research & Development, LLC $4,250.00 08/25/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274949
Principal investigator 1 Janssen Research & Development, LLC $1,212.00 08/08/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275055
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635279
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635281
Principal investigator 1 Janssen Research & Development, LLC $7,125.00 07/23/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275034
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635287
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635289
Principal investigator 1 Janssen Research & Development, LLC $7,697.00 06/20/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275063
Principal investigator 1 Janssen Research & Development, LLC $404.00 06/09/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274969
Principal investigator 1 Boehringer Ingelheim International GmbH $2,700.00 06/02/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635271
Principal investigator 1 Boehringer Ingelheim International GmbH $1,350.00 06/02/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635273
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 06/02/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635275
Principal investigator 1 Boehringer Ingelheim International GmbH $1,350.00 06/02/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635277
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635267
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635269
Principal investigator 1 Janssen Research & Development, LLC $5,111.00 05/21/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274914
Principal investigator 1 PFIZER INC. $3,858.36 05/13/2025 Non-covered Recipient Entity
Texas Health Research Education Institute
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1228764361
Principal investigator 1 Boehringer Ingelheim International GmbH $1,396.00 05/02/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635261
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635263
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635265
Principal investigator 1 Janssen Research & Development, LLC $7,661.00 04/23/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274922
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,404.00 04/08/2025 Non-covered Recipient Entity
TEXAS HEALTH RESEARCH AND EDUCATION INSTITUTE
Dapagliflozin in Acute Decompensated Heart Failure No dispute reported 06/30/2026 1185551353
Principal investigator 1 Janssen Research & Development, LLC $346.00 04/07/2025 Non-covered Recipient Entity
TEXAS HEALTH RESEARCH & EDUCATION I NSTITUTE IRB
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175404181
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635257
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635259
Principal investigator 1 PFIZER INC. $156.00 03/22/2025 Non-covered Recipient Entity
Texas Health Research Education Institute
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1228780205
Principal investigator 1 Janssen Research & Development, LLC $5,425.00 03/21/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274975
Principal investigator 1 Janssen Research & Development, LLC $5,850.00 03/14/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274930
Principal investigator 1 Janssen Research & Development, LLC $692.00 03/03/2025 Non-covered Recipient Entity
TEXAS HEALTH RESEARCH & EDUCATION I NSTITUTE IRB
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175404204
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635243
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635245
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 02/25/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635249
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 02/25/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635251
Principal investigator 1 Boehringer Ingelheim International GmbH $2.61 02/25/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635253
Principal investigator 1 Boehringer Ingelheim International GmbH $6.58 02/25/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635255
Principal investigator 1 Eli Lilly and Company $151.12 02/25/2025 Non-covered Recipient Entity
LEADING EDGE RESEARCH
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187885370
Principal investigator 1 Janssen Research & Development, LLC $9,100.00 02/19/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275196
Principal investigator 1 Janssen Research & Development, LLC $173.00 02/17/2025 Non-covered Recipient Entity
TEXAS HEALTH RESEARCH & EDUCATION I NSTITUTE IRB
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175404199
Principal investigator 1 Janssen Research & Development, LLC $173.00 02/10/2025 Non-covered Recipient Entity
TEXAS HEALTH RESEARCH & EDUCATION I NSTITUTE IRB
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175404166
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,127.46 02/10/2025 Non-covered Recipient Entity
TEXAS HEALTH PHYSICIANS GROUP
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310815
Principal investigator 1 Janssen Research & Development, LLC $1,004.00 02/07/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175274943
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635239
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635241
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635247
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 01/31/2025 Non-covered Recipient Entity
TEXAS HEALTH RESEARCH & EDUCATION I NSTITUTE IRB
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175404172
Principal investigator 1 Janssen Research & Development, LLC $111.00 01/31/2025 Non-covered Recipient Entity
TEXAS HEALTH RESEARCH & EDUCATION I NSTITUTE IRB
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175404185
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,985.80 01/28/2025 Non-covered Recipient Entity
TEXAS HEALTH RESEARCH EDUCATION I INST
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190309658
Principal investigator 1 PFIZER INC. $1,356.13 01/28/2025 Non-covered Recipient Entity
Texas Health Research Education Institute
A PHASE 2 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED 4ARM STUDY TO INVESTIGATE SYMPTOMS FUNCTION HEALTHRELATED QUALITY OF LIFE AND SAFETY WITH REPEATED SUBCUTANEOUS ADMINISTRATION OF PONSEGROMAB VERSUS PLACEBO IN ADULT PARTICIPANTS WITH HEART FAILURE No dispute reported 06/30/2026 1228801894
Principal investigator 1 Boehringer Ingelheim International GmbH $1,350.00 01/24/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635221
Principal investigator 1 Boehringer Ingelheim International GmbH $691.00 01/24/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635223
Principal investigator 1 Boehringer Ingelheim International GmbH $1,350.00 01/24/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635225
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 01/24/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635227
Principal investigator 1 Boehringer Ingelheim International GmbH $691.00 01/24/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635229
Principal investigator 1 Janssen Research & Development, LLC $7,255.00 01/22/2025 Non-covered Recipient Entity
Tx Hlth Rsrch & Educ Inst
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175275040
Principal investigator 1 Eli Lilly and Company $12,497.00 01/21/2025 Non-covered Recipient Entity
LEADING EDGE RESEARCH
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187885972
Principal investigator 1 Boehringer Ingelheim International GmbH $2,025.00 01/17/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635215
Principal investigator 1 Boehringer Ingelheim International GmbH $2,025.00 01/17/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635217
Principal investigator 1 Boehringer Ingelheim International GmbH $13,500.00 01/17/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635219
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635231
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635233
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635235
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Texas Health Resources-Internal Medicine
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220635237